Literature DB >> 19690559

Diabetes: HOME reveals new data on a cornerstone of treatment.

William T Cefalu.   

Abstract

A question often asked by health-care providers is whether metformin has added benefits if continued after patients with type 2 diabetes mellitus switch to insulin. Beneficial effects on macrovascular end points observed in response to sustained metformin therapy argue in favor of this approach, according to new research from The netherlands.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19690559     DOI： 10.1038/nrendo.2009.154

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  9 in total

Review 1.  PPARs and the complex journey to obesity.

Authors:  Ronald M Evans; Grant D Barish; Yong-Xu Wang
Journal:  Nat Med       Date:  2004-04       Impact factor: 53.440

2.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

3.  Combination of insulin and metformin in the treatment of type 2 diabetes.

Authors:  Michiel G Wulffelé; Adriaan Kooy; Philippe Lehert; Daniel Bets; Jeles C Ogterop; Bob Borger van der Burg; Ab J M Donker; Coen D A Stehouwer
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

4.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

5.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

6.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic.

Authors:  Youfa Wang; May A Beydoun; Lan Liang; Benjamin Caballero; Shiriki K Kumanyika
Journal:  Obesity (Silver Spring)       Date:  2008-07-24       Impact factor: 5.002

8.  Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.

Authors:  Adriaan Kooy; Jolien de Jager; Philippe Lehert; Daniël Bets; Michiel G Wulffelé; Ab J M Donker; Coen D A Stehouwer
Journal:  Arch Intern Med       Date:  2009-03-23

9.  Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 17.152
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.